IndexBox releases a 2035 forecast for human IFN-γ ELISA kits

Impact level

⚪ Background

What happened

IndexBox published a report on October 8, 2026, forecasting a 6.2% compound annual growth rate for the human IFN-γ ELISA kit market from 2026 to 2035, with the market index reaching 182 in 2035 (2025=100). Growth drivers include IFN-γ's role as a pharmacodynamic biomarker in immuno-oncology research, demand for GMP-grade kits in cell and gene therapy manufacturing, and the diagnosis of infectious diseases such as tuberculosis. Asia-Pacific is expected to contribute the largest increase in demand, while growth in North America and Europe is expected to be more moderate. [1]

Involves:Human IFN-γ ELISA kit

Seller impact

• FactThe report says clinical diagnostics and bioprocess monitoring are growing faster than research use. GMP-grade and IVD certifications create barriers to entry, while high switching costs and bottlenecks in the supply of antibody pairs constrain new suppliers from entering the market. [1]
• InferenceAsia-Pacific is expected to contribute the largest incremental demand, but local suppliers still rely on imported high-quality reagents. This means upstream antibody and certification capabilities are the main bottlenecks, while pricing and pricing power are concentrated among multinational suppliers with regulatory qualifications. [1]

Evidence that would disprove the assessment

• Assessment 1：This assessment would no longer hold if a later edition lowered the CAGR forecast or indicated that alternative technologies were accelerating their displacement of these kits.
• Assessment 2：This inference should be revised if public evidence emerges that local suppliers have obtained GMP or IVD certification and are replacing imports. A review is recommended in the next two weeks.